28mon MSN
MindRank in phase 3 trial with China’s first AI-assisted new drug, cutting R&D costs by 60%
The company was aiming for approval in the second half of 2028, paving the way for a market launch in 2029 Hangzhou-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback